EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Abivax's enterprise value is €584.72 Mil.
Abivax's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Therefore, Abivax's EV-to-Revenue for today is .
The historical rank and industry rank for Abivax's EV-to-Revenue or its related term are showing as below:
During the past 11 years, the highest EV-to-Revenue of Abivax was 19590.33. The lowest was 229.97. And the median was 6540.51.
CHIX:ABVXp's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.18 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-25), Abivax's stock price is €16.22.
Abivax's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Therefore, Abivax's PS Ratio for today is .
Abivax EV-to-Revenue Historical Data
The historical data trend for Abivax's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Abivax's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abivax's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abivax's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Abivax's EV-to-Revenue falls into.
Abivax's current Enterprise Value is €584.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Abivax's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abivax's share price for today is €16.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abivax EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Abivax's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Abivax SA is a France-based biotechnology company. It is focused on using antiviral technology platforms targeting the immune system to eliminate viral diseases. The antiviral and immunotherapeutic products that the group develops result from three technology platforms; a Modulation of RNA Biogenesis platform, an Immune stimulation platform, and a Polyclonal antibody platform. The Antiviral platform targets the formation of Ribonucleoprotein in the nucleus or the cytoplasm of the infected cell during viral infection, the Immune stimulation platform focuses on invariant natural killer agonists and the Polyclonal antibodies platform generates neutralizing antibodies against different viruses. Its current pipeline includes ABX464 for Ulcerative Colitis and ABX196 for Hepatocellular Carcinoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:ABVXP has been successfully added to your 